Objective: This study compared the effects of combination statin and fibrate therapy with either statin or fibrate monotherapy on lipid profiles in patients with impaired glucose tolerance (IGT) and a high risk for cardiovascular disease.
Introduction
Patients with impaired glucose tolerance (IGT) have an increased prevalence of cardiovascular disease due to atherosclerosis [1] . This increase is attributable, in part, to associated risk factors that include hypertension and dyslipidemia. It is well known that a lot of patients with IGT have dyslipidemia without any symptoms. The dyslipidemia is characterized by elevated triglycerides (TG), low levels of high density lipoprotein (HDL) cholesterol, and high levels of low density lipoprotein (LDL) cholesterol. Statins inhibit HMG-CoA reductase and prevent the formation of mevalonate, the rate-limiting step of sterol synthesis. HMG-CoA reductase inhibition increase LDL-cholesterol clearance from plasma and decrease hepatic production of LDL. While statin therapy has beneficial effects in patients with type 2 diabetes [2] , the prevalence of cardiovascular events remains elevated even in statin-treated patients with glucose intolerance [2] . In contrast, it has been reported that fibrates reduce the rate of cardiovascular events in patients with glucose intolerance [3] . The mechanism of action of fibrates involves interaction with the nuclear transcription factor PPARα that regulates the transcription of the LPL, apo CII and apo AI genes. Fibrates are able to inhibit the glucuronidation of statins. Thus, the combination of fibrates with statins may increase the risk of myotoxicity. In the present study, we investigated the effects of combination treatment with a statin and a fibrate in Japanese patients with impaired glucose tolerance and increases in both TG and LDL cholesterol levels.
Methods

Study Subjects
The study group comprised 45 subjects (mean age 67 +/− 11 yr) who were admitted to our hospital for examination and care of dyslipidemia. No subject had previously been diagnosed with diabetes or cardiovascular disease, with the fasting glucose level of all the subjects being < 126 mg/dl. A 75 g oral glucose tolerance test was carried out in order to assess glycaemic control and the associated risk of coronary artery disease. Both IGT and diabetes were diagnosed according to the criteria of the World Health Organization [4] . The patients who had renal dysfunction (Serum Creatinine > 1.5 mg/dL) were excluded from the present study. Three patients had diabetes [DM] and 42 had IGT. The characteristics of the patients are shown in Table 1 . There were no significant differences between the three groups. Written, informed consent was obtained from each patient before the study was commenced. The procedures used in the study were approved by the ethics committee at our institution.
Study Design
Data for the study were collected during a 75 g oral glucose tolerance test. After the patient had fasted for 12 to 14 hours, blood samples were obtained before and 0.5, 1, and 2 hours after administration of a 75 g glucose equivalent load (Trelan-G, Takeda, Japan). Plasma glucose concentrations were determined by the glucose oxidase method using an autoanalyzer. Fasting serum total cholesterol and TG concentrations were measured enzymatically, while serum LDL and HDL-cholesterol concentrations were measured by heparin-Ca 2+ /Ni 2+ precipitation [5, 6] . Remnant lipoproteins were isolated by applying the fasting serum samples to an immunoaffinity mixed gel, which contained anti-apo-A1 and anti-apoB-100 monoclonal antibodies (Japan Immunoresearch Laboratories) [7] .
Patients were randomly allocated to receive either rosuvastatin (2.5 mg/day), bezafibrate (200 mg/day) or rosuvastatin (2.5 mg/day) plus bezafibrate (200 mg/day). The patients were also provided with dietary advice and were allowed to take medications prescribed for other conditions, with the exception of lipid-lowering drugs. A check of the patients' condition was carried out every month and lipid profiles were measured every 3 months.
Statistical Analysis
Comparison of the data in the 3 groups was performed using one-way analysis of variance (ANOVA), followed by the Bonferroni multiple comparison test. Changes in the variables were assessed by 2-way ANOVA with repeated measures, followed by post hoc testing with Scheffe's test. Statistical significance was defined as p < 0.05.
Results
The 45 patients with IGT and dyslipidemia (men 25, women 20, mean age 61.7 ± 2.4 yr) were assigned randomly to 3 groups for the 6-month treatment period (bezafibrate monotherapy: men 8, women 7, mean age 62.5 yr; rosuvastatin monotherapy: men 8, women 7, mean age 60.6 yr; bezafibrate plus rosuvastatin combined therapy: men 9, women 6, mean age 61.5 yr). As shown in Figure 1 all three therapies decreased LDL-cholesterol levels (bezafibrate monotherapy: 160 ± 15 to 149 ± 12 mg/dl, p < 0.01; rosuvastatin monotherapy: 162 ± 14 to 141 ± 14 mg/dl, p < 0.01; bezafibrate plus rosuvastatin combined therapy: 161 ± 14 to 141 ± 14g/dl, p < 0.01). Similarly, all three therapies reduced TG levels (bezafibrate monotherapy: 235 ± 18 to 179 ± 19 mg/dl, p < 0.01; rosuvastatin monotherapy: 222 ± 17 to 191 ± 19 mg/dl, p < 0.01; bezafibrate plus rosuvastatin combined therapy: 231 ± 17 to 171 ± 19 mg/dl, p < 0.01). The levels of HDL-cholesterol did not change during the study (bezafibrate monotherapy: 43 ± 1.2 to 42 ± 1.3 mg/dl; rosuvastatin monotherapy: 40 ± 1.1 to 41 ± 1.0 mg/dl; bezafibrate plus rosuvastatin therapy: 40 ± 1.3 to 40 ± 1.2 mg/dl). The levels of remnant like particles (RLP)-cholesterol decreased with bezafibrate monotherapy (9.8 ± 1.1 to 6.6 ± 1.2 mg/dl, p < 0.01) and bezafibrate and rosuvastatin combined therapy (9.9 ± 1.2 to 6.8 ± 1.4 mg/dl, p < 0.01). As shown in Figure 2 , rosuvastatin monotherapy was associated with a non-significant trend of decreasing RLP-cholesterol levels (9.7 ± 1.1 to 9.4 ± 1.3 mg/dl). Fasting glucose levels also tended to decrease in the three groups, especially with bezafibrate monotherapy and bezafibrate and rosuvastatin combined therapy (bezafibrate monotherapy: 119 ± 3.2 to 112 ± 3.3 mg/dl; rosuvastatin monotherapy: 120 ± 3.4 to 118 ± 3.1 mg/dl; bezafibrate plus rosuvastatin combined therapy: 119 ± 3.3 to 110 ± 3.7 mg/dl). None of these changes were statistically significant. The levels of creatine phosphokinase, lactate dehydrogenase, and creatinine did not change during the study (Figure 3 ).
Discussion
In this study we showed that combination lipid therapy had beneficial effects on lipid profiles in Japanese patients with IGT patients without causing any major adverse effects. Numerous observational studies have shown an association between TG levels and increased risk of cardiovascular morbidity and mortality [8, 9] . The clinical benefit of TG reduction with fibrates has been assessed in several large interventional studies [10, 11] . Bezafibrate is a lipid-modifying agent that has marked effects on triglyceride levels. By activating the peroxisome proliferator activator receptors, bezafibrate enhances the clearance of triglyceride-rich lipoproteins by inducing expression of lipoprotein lipase and reducing secretion of very low-density lipoprotein from the liver [12] . In the present study, significant TG reduction was noted in every patient, with the magnitude of this reduction being greater in patients treated with bezafibrate and bezafibrate plus rosuvastatin combined therapy.
Due to their TG lowering effect, fibrates offer an effective treatment strategy for achieving treatment targets, beyond a reduction in LDL cholesterol levels. In clinical practice, the beneficial effects associated with a fibrate may be maximized when used in combination with a statin. Currently, statins are usually the first class of lipid-lowering agents used in patients with coronary heart disease or in those at high risk of developing this disorder. It is possible that patients with coronary heart disease and those at high risk of atherosclerosis may benefit from combined treatment with a statin and fibrate. In the present study, the combination of a statin and fibrate was well tolerated with no major safety concerns. On the basis of these results, we consider the effects of combination therapy for cardiovascular disease should be tested prospectively in the future.
In the present study, HDL cholesterol levels tended to increase, while fasting blood glucose concentrations tended to decrease. Previous studies have also reported that HDL cholesterol levels increase and fasting blood glucose concentrations decrease after administration of lipid-lowering agents, such as statins and fibrates [11, 13] . As the present study included only a small number of patients and was of relatively short duration, further studies are required to clarify the effects of either statin plus fibrate, statin alone, or fibrate alone on HDL cholesterol and fasting blood glucose levels.
The relationship between total cholesterol and LDL cholesterol and the development and progression of atherosclerosis and cardiovascular disease has been demonstrated in a number of clinical and epidemiological studies. Furthermore, the benefit of LDL cholesterol reduction is supported clearly by evidence of a significant decrease in cardiovascular events, including cardiovascular mortality, achieved by reducing LDL cholesterol with statin therapy [14] [15] [16] [17] [18] . The most potent triglyceridelowering agents available are fibrates, with the combination of a fibrate and statin providing complementary lipid-lowering effects. In numerous studies, this combination has been shown to control elevations in both LDL cholesterol and triglyceride levels [19] [20] [21] [22] [23] . However, concomitant use of a fibrate and a statin has been associated with an increased risk of myopathy. It appears that this risk may differ depending on which statin and fibrate are administered [24, 25] . In the present study, we used the combination of bezafibrate (200 mg/day) and rosuvastatin (2.5 mg/day), and showed that administration of the two drugs at these dosages was both effective and safe.
There is evidence that triglyceride-rich lipoproteins are atherogenic and are a strong risk factor for cardiovascular disease. We and others have shown that among the triglyceride-rich lipoproteins, remnant lipoproteins, especially from very-rich lipoproteins (VLDL), have a strong atherogenic effect [26] [27] [28] [29] [30] [31] [32] . In the past it has been difficult to assay levels of remnant lipoprotein due to their heterogeneous properties. However, a simple and reliable technique for measuring levels of remnant like lipoprotein particles (RLP) cholesterol using an immunoseparation method has now been developed. It has been shown that this technique isolates mainly remnants of VLDL from fasting serum, with high RLP cholesterol levels predicting future coronary events in patients with coronary artery disease [13] . It has also been shown that high levels of RLP cholesterol are an independent risk for cardiovascular events in patients with glucose intolerance [32] . Previous studies reported a significant association between reduced RLP cholesterol levels and a decrease in cardiovascular events [13, 32] . The present study showed that bezafibrate treatment effectively reduced RLP cholesterol levels, while treatment with either rosuvastatin alone or bezafibrate plus rosuvastatin also resulted in a reduction in RLP cholesterol levels. However, the magnitude of the reduction in RLP cholesterol levels was greater with bezafibrate plus rosuvastatin than rosuvastatin alone. In the present study, the majority of patients had insulin resistance. Fibrate therapy may have a tendency to improve insulin sensitivity in addition to modulating TG levels, thereby leading to a reduction in RLP cholesterol levels.
In conclusion, the combination of bezafibrate and rosuvastatin has beneficial effects in patients with mixed dyslipidemia who are at high risk of further atherosclerosis complications. However, the present results need to be confirmed by further studies on a larger number of patients.
